Author(s): Stintzing S, Heinemann V
Abstract Share this page
Abstract Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR-resistant tumors, but it remains unclear whether a higher toxicity is outweighed by those advantages. ©2015 American Association for Cancer Research.
This article was published in Cancer Discov
and referenced in Journal of Integrative Oncology